Browse Studies — Arctuva

Long-term Follow-up After Adoptive Transfer of Genetically Modified Cell Products

Human gene therapy products are designed to achieve therapeutic effect through genetic modifications of human cells using retroviral or lentiviral vectors, res…

Relapsed Hematologic MalignancyRefractory Hematologic Malignancy

Estimated

~$10 – $750

St. Jude Children's Research HospitalNCT05713214

Observational

Evaluating Patient-Reported Outcomes and Wearable Data Among Individuals With Relapsed/Refractory Multiple Myeloma

This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adu…

Multiple MyelomaRelapsed Hematologic Malignancy

Estimated

~$10 – $7,500

Pack HealthNCT05956457

Phase 1

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or…

Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more

Estimated

~$10 – $8,750

Curis, Inc.NCT03328078